论文信息 - A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer - 字舞流文

A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer

J. Baselga | Y. Bang | R. Salgia | D. Juric | J. Tabernero | Sunil Sharma | Philippe Bédard | A. Zubel | M. Alsina | Q. Sheng | Chia‐Chi Lin | Se-Hoon Lee | E. Cohen | K. Reynolds | G. Blumenschein | I. Garrido-Laguna | D. Graham | A. Morozov | Xianbin Tian | T. Ramkumar | A. Seroutou | R. Fernandez